Hendrik Ruge1,2, MD; Magdalena Erlebach1,2, MD; Patrick Mayr3, MD; Sabine Bleiziffer4, MD, PhD; Rüdiger Lange1,2, MD, PhD
1. Department of Cardiovascular Surgery, INSURE (Institute for Translational Cardiac Surgery), German Heart Center, TUM, Munich, Germany; 2. Department of Cardiovascular Surgery, German Heart Center Munich, TUM, Munich, Germany; 3. Department of Anaesthesiology, German Heart Center Munich, TUM, Munich, Germany; 4. Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany
Introduction
Utilisation of transcatheter aortic valve replacement (TAVR) is increasing. Vascular complications after transfemoral TAVR are still of concern. The majority are related to the large bore puncture site1. Currently, large bore arteriotomy closure relies on suture-based techniques, such as the Perclose ProGlide® or Prostar® XL devices (Abbott Vascular, Santa Clara, CA, USA). Closure devices such as MANTA® (Teleflex, Wayne, PA, USA) or PerQSeal® (Vivasure Medical, Galway, Ireland) are designed to seal large bore arteriotomies and have recently become available. The novel InClosure® vascular closure device (VCD) (InSeal Medical, Caesarea, Israel) provides haemostasis ...